Floatz logo

DACTOLISIB

Chronic Myelogenous Leukemia With Crisis of Blast Cells

Goethe UniversitySmall moleculePhase 1Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

43 Active assets in the Chronic Myelogenous Leukemia With Crisis of Blast Cells cohort.

Asset / SponsorPhaseRating
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Imatinib
The University of Hong Kong
Phase 2BB
TACROLIMUS
University of Michigan Rogel Cancer Center
Phase 2BB
Nilotinib
The University of Hong Kong
Phase 2BB

View all 50 →

Same molecule, other indications

DACTOLISIB is also rated in:

breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →
castration-resistant prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
pancreatic neuroendocrine tumorDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →